429 related articles for article (PubMed ID: 1945409)
21. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
Spencer CA; LeStrange RC; Novak U; Hayward WS; Groudine M
Genes Dev; 1990 Jan; 4(1):75-88. PubMed ID: 2307371
[TBL] [Abstract][Full Text] [Related]
22. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
23. NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.
Ji L; Arcinas M; Boxer LM
Mol Cell Biol; 1994 Dec; 14(12):7967-74. PubMed ID: 7969136
[TBL] [Abstract][Full Text] [Related]
24. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
26. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
27. c-myc Suppression in Burkitt's lymphoma cells.
Simonsson T; Henriksson M
Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
[TBL] [Abstract][Full Text] [Related]
28. [Epstein-Barr virus and Burkitt's lymphoma].
Joab I
Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
[TBL] [Abstract][Full Text] [Related]
29. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
30. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
31. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
32. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
33. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
Yano T; Sander CA; Clark HM; Dolezal MV; Jaffe ES; Raffeld M
Oncogene; 1993 Oct; 8(10):2741-8. PubMed ID: 8397370
[TBL] [Abstract][Full Text] [Related]
34. CAD, a c-Myc target gene, is not deregulated in Burkitt's lymphoma cell lines.
Mac SM; Farnham PJ
Mol Carcinog; 2000 Feb; 27(2):84-96. PubMed ID: 10657901
[TBL] [Abstract][Full Text] [Related]
35. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
36. TATA box and Sp1 sites mediate the activation of c-myc promoter P1 by immunoglobulin kappa enhancers.
Geltinger C; Hörtnagel K; Polack A
Gene Expr; 1996; 6(2):113-27. PubMed ID: 8979089
[TBL] [Abstract][Full Text] [Related]
37. Lack of mutagenicity and clastogenicity of PNAEmu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma.
Boffa LC; Menichini P; Bolognesi C; Cutrona G; Roncella S; Damonte GL; Millo E; Mariani MR; Matis S; Russo D; Ciliutti P; Ferrarini M
Mutat Res; 2007 Apr; 628(2):129-37. PubMed ID: 17267263
[TBL] [Abstract][Full Text] [Related]
38. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract][Full Text] [Related]
39. Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3' enhancer motif PU.
Wittekindt NE; Hörtnagel K; Geltinger C; Polack A
Nucleic Acids Res; 2000 Feb; 28(3):800-8. PubMed ID: 10637333
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
Arcinas M; Heckman CA; Mehew JW; Boxer LM
Cancer Res; 2001 Jul; 61(13):5202-6. PubMed ID: 11431360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
